|
rs121913444
|
|
A |
0.750 |
CausalMutation |
CLINVAR |
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
|
15118125 |
2004 |
|
rs121913444
|
|
A |
0.750 |
CausalMutation |
CLINVAR |
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
|
15118073 |
2004 |
|
rs121913444
|
|
A |
0.750 |
CausalMutation |
CLINVAR |
"EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib."
|
15329413 |
2004 |
|
rs121913444
|
|
A |
0.750 |
CausalMutation |
CLINVAR |
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.
|
19922469 |
2010 |
|
rs121913444
|
|
A |
0.750 |
CausalMutation |
CLINVAR |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
|
22753918 |
2012 |
|
rs121913444
|
|
|
0.750 |
GeneticVariation |
BEFREE |
Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC).
|
24353160 |
2013 |
|
rs121913444
|
|
A |
0.750 |
CausalMutation |
CLINVAR |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
|
23102728 |
2013 |
|
rs121913444
|
|
|
0.750 |
GeneticVariation |
BEFREE |
Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
|
24419415 |
2014 |
|
rs121913444
|
|
|
0.750 |
GeneticVariation |
BEFREE |
EGFR L858M/L861Q mutations in cis were detected in the tumor of a patient with NSCLC.
|
28088511 |
2017 |
|
rs121913444
|
|
|
0.750 |
GeneticVariation |
BEFREE |
We here present an NSCLC patient found to be positive for double uncommon EGFR mutations (G719X and L861Q) by clinical genomic sequencing analysis of a pleural effusion specimen who showed a durable response to the EGFR-TKI afatinib.
|
30255614 |
2018 |
|
rs121913444
|
|
|
0.750 |
GeneticVariation |
BEFREE |
The results of the present case support the effectiveness and safety of low-dose afatinib in elderly patients with EGFR L861Q mutation-positive NSCLC.
|
31779047 |
2020 |